Renal drug clearance in preterm neonates: Relation to prenatal growth

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 284-291

  Allegaert, Karel ^a,f   Anderson, Brian J ^b   Van Den Anker, John N ^c,d,e   Vanhaesebrouck, Sophie ^a   De Zegher, Francis ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Glomerular filtration rate; Intrauterine growth restriction; Preterm neonate; Renal drug clearance; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; GLYCOPEPTIDE; IBUPROFEN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN SYNTHASE INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BIRTH WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HOSPITAL INFECTION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL PERIOD; PREMATURITY; PRENATAL GROWTH; PRIORITY JOURNAL; SMALL FOR DATE INFANT; INTRAUTERINE GROWTH RETARDATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY;

AMIKACIN; ANTI-BACTERIAL AGENTS; DRUG MONITORING; FETAL GROWTH RETARDATION; GLOMERULAR FILTRATION RATE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; METABOLIC CLEARANCE RATE; VANCOMYCIN;

EID: 34447513694     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31806db3f5     Document Type: Article

References (49)

1. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
2. Bergstein JM. Introduction to glomerular diseases. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. Philadelphia: WB Saunders; 2000:1574-1575.
3. Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92:705-712.
4. Sonntag J, Prankel B, Waltz S. Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g. Eur J Pediatr. 1996;155:815-819.
5. van der Heijden AJ, Grose WF, Ambagtsheer JJ, et al. Glomerular filtration rate in the preterm infant: the relation to gestational and postnatal age. Eur J Pediatr. 1988;148:24-28.
6. Van den Anker JN, de Groot R, Broerse HM, et al. Assessment of glomerular filtration rate in preterm infants by serum creatinine: comparison with inulin clearance. Pediatrics. 1995;96:1156-1158.
7. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol. 2004;28:132-140.
8. Langhendries JP, Battisti O, Bertrand JM, et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate. 1998;74:351-362.
9. Treluyer JM, Merle Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002;46:1381-1387.
10. Bleyzac N, Varnier V, Labaune JM, et al. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol. 2001;57:499-504.
11. Padovani EM, Pistolesi C, Fanos V, et al. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther. 1993;20:167-173.
12. Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother. 1990;34:265-268.
13. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417-440.
14. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81:F221-F227.
15. Frattarelli DA, Ergun H, Lulic-Botica M, et al. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr Infect Dis J. 2005;24:979-983.
16. Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48:1159-1167.
17. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41:927-934.
18. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther. 1985;38:680-685.
19. Zarowitz BJ, Robert S, Peterson EL. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother. 1992;26:1205-1210.
20. Pachi A, Lubrano R, Maggi E, et al. Renal tubular damage in fetuses with intrauterine growth retardation. Fetal Diagn Ther. 1993;8:109-113.
21. Hinchliffe SA, Lynch MR, Sargent PH, et al. The effect of intrauterine growth retardation on the development of renal nephrons. Br J Obstet Gynaecol. 1992;99:296-301.
22. Robinson D, Weiner CP, Nakamura KT, et al. Effect of intrauterine growth retardation on renal function on day one of life. Am J Perinatol. 1990;7:343-346.
23. Narang A, Bhakoo ON, Majumdar S, et al. Renal function in SFD and AFD preterm babies. Indian Pediatr. 1993;30:201-205.
24. Silver LE, Decamps PJ, Korst LM, et al. Intrauterine growth restriction is accompanied by decreased renal volume in the human fetus. Am J Obstet Gynecol. 2003;188:1320-1325.
25. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819-829.
26. Allegaert K, Anderson BJ, Cossey V, et al. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol. 2006;61:39-48.
27. Anderson BJ, Allegaert K, van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63:75-84.
28. Devlieger H, Martens G, Bekaert A, et al. Perinatal activities in Flanders. 1996;94-116.
29. van Overmeire B, Allegaert K, Casaer A, et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:1945-1949.
30. Beal SL, Sheiner LB, Boeckmann A. Nonmem User's Guide. San Francisco: Division of Pharmacology, University of California, 1999.
31. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329-332.
32. Anderson BJ, Meakin GH. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth. 2002;12:205-219.
33. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122-126.
34. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677-1679.
35. Peters HP. Physiological correlates of size. In: Beck E, Birks HJB, Conner EF, eds. The Ecological Implications of Body Size. Cambridge: Cambridge University Press, 1983:48-53.
36. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
37. Simeoni U, Zetterstrom R. Long-term circulatory and renal consequences of intrauterine growth restriction. Acta Paediatr. 2005;94:819-824.
38. Keijzer-Veen MG, Schrevel M, Finken MJ, et al. Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. J Am Soc Nephrol. 2005;16:2762-2768.
39. Bauer R, Walter B, Bauer K, et al. Intrauterine growth restriction reduces nephron number and renal excretory function in newborn piglets. Acta Physiol Scand. 2002;176:83-90.
40. Bassan H, Trejo LL, Kariv N, et al. Experimental intrauterine growth retardation alters renal development. Pediatr Nephrol. 2000;15:192-195.
41. Merlet-Benichou C, Gilbert T, Muffat-Joly M, et al. Intrauterine growth retardation leads to permanent nephron deficit in the rat. Pediatr Nephrol. 1994;8:175-180.
42. Bauer R, Walter B, Zwiener U. Comparison between inulin clearance and endogenous creatinine clearance in newborn normal weight and growth restricted newborn piglets. Exp Toxicol Pathol. 2000;52:367-372.
43. Bauer R, Walter B, Ihring W, et al. Altered renal function in growthrestricted newborn piglets. Pediatr Nephrol. 2000;14:735-739.
44. van den Anker JN, Hop WC, de Groot R, et al. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res. 1994;36:578-581.
45. van den Anker JN, Schoemaker RC, Hop WC, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58:650-659.
46. Huisman-de Boer JJ, van den Anker JN, Vogel M, et al. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob Agents Chemother. 1995;39:431-434.
47. Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics. 1999;103:e49.
48. de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-194.
49. Allegaert K, Anderson B. Limited predictability of aminoglycoside pharmacokinetics in preterm neonates at birth. Eur J Clin Pharmacol. 2006;62:1011-1012.